Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
Analog Devices Nears $1.5B Acquisition of AI Chip Firm Empower Semiconductor 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Elliott Targets Bio-Rad as Shares Continue to Struggle 
Samsung Shares Drop as Labor Union Confirms Planned Strike 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
JERSEY CITY, N.J., Sept. 20, 2016 -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference at the Sofitel New York Hotel on Tuesday, September 27, 2016 at 3:00 p.m. ET.
A live webcast will be available on the investors section of the Company's website: www.SCYNEXIS.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of serious and life-threatening invasive fungal infections. For more information, visit www.SCYNEXIS.com.
CONTACT: Media Relations Blair Atkinson MacDougall Biomedical Communications Tel: 781.235.3060 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212.203.4433 [email protected]
